Giving Alzheimer's the old one-two

Cell
Michael S Wolfe, D J Selkoe

Abstract

A dual goal for treating Alzheimer's disease (AD) is to decrease deposition of neurotoxic amyloid beta-peptide in the brain and to boost repair of damaged neurons. Donmez et al. (2010) now show that SIRT1 may mediate both processes by deacetylating the transcription factor retinoic acid receptor beta, a potential new therapeutic target for AD.

References

Apr 19, 2008·Cold Spring Harbor Symposia on Quantitative Biology·L Guarente
Apr 22, 2009·Cell·Raphael Kopan, Maria Xenia G Ilagan
Apr 23, 2010·Aging Cell·Gizem Donmez, Leonard Guarente
May 1, 2010·Nature Reviews. Drug Discovery·Martin Citron
Jun 16, 2010·Neuron·Karen H Ashe, Kathleen R Zahs

❮ Previous
Next ❯

Citations

Sep 26, 2013·Nature Reviews. Cancer·Benjamin Beck, Cédric Blanpain
Dec 18, 2015·Neurochemical Research·Grzegorz A CzapskiRobert P Strosznajder
Aug 19, 2021·Journal of Chemical Neuroanatomy·Yaochen ChuangYouhua Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.